Search | Clinical Trials Finder

Conditions: Assessment of Fetal Movement, Pregnancy, Pregnancy Complications, Pregnancy Complications Affecting Fetus (Diagnosis), Stillbirth, Stillbirth and Neonatal Mortality, Fetal Movement
Interventions: Smartphone Application; Device
Lead sponsor: Kenneth Moise MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Austin, Texas • Galveston, Texas • Houston, Texas

Conditions: Alzheimer Disease, Aging
Interventions: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Headaches Associated With Subarachnoid Hemorrhage (SAH)
Interventions: Lidocaine hydrochloride, Methylprednisolone sodium succinate; Drug
Lead sponsor: Daniel Raper, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Physical Activity, Cognition, Habits
Interventions: Non-PA Action Planning, PA Action Planning, Consistency in Action Plans; Behavioral
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: 60 Years and older
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)
Interventions: Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide, Doxorubicin, Prednisone, Pegfilgrastim; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 70 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pulmonary Arterial Hypertension (PAH)
Interventions: Tiprelestat (5 mg), Placebo (1 mL 0.9% saline solution), Tiprelestat (10 mg); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: Tucson, Arizona • San Francisco, California • Stanford, California + 7 more

Conditions: Sexual Dysfunction
Interventions: Rosy app; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Traumatic Brain Injury (mTBI), Concussion, Mild Traumatic Brain Injury
Interventions: Motor Activation Physical Therapy for mTBI, Standard of Care Physical Therapy for mTBI; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Portland, Oregon • Salt Lake City, Utah

Conditions: Blood Pressure, Relaxation, Virtual Reality
Interventions: Virtual Reality Relaxation, Video Meditation, Live Guided; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Peripheral Arterial Disease, Peripheral Neuropathy
Interventions: Replexa shortwave diathermy; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes Mellitis, Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus (T1DM), Exercise Physiology
Interventions: Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Heart Failure
Interventions: Video Based Visits, Remote Self-Care Education, Remote Patient Monitoring; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neoplasm Cervix
Interventions: Curcumin C3 Complex, Placebo; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 21 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Interventions: BMS-986353, Fludarabine Phosphate, Cyclophosphamide; Biological · Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas • Seattle, Washington

Conditions: Myocarditis, Ischemia, Chest Pain
Interventions: Imaging; Diagnostic Test
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Loma Linda, California • Overland Park, Kansas • The Bronx, New York + 1 more

Conditions: Digital Nerve Injury, Nerve Reconstruction
Interventions: ReFeel; Device
Lead sponsor: OrthoCarolina Research Institute, Inc.; Other
Eligibility: 18 Years to 69 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride; Drug · Procedure
Lead sponsor: Laura Huppert, MD, BA; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Birth; Induced
Interventions: BASE, LEAD, TEAM; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Wisdom Teeth, Wisdom Teeth Extraction or Jaw Implant
Interventions: NEUROCUPLE™ Patch, Sham Patch; Device
Lead sponsor: nCap Medical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Child Obesity
Interventions: Produce Prescription Group, Control Group; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 12 Years to 17 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: Nivolumab, Relatlimab, Ipilimumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Knee Arthritis, Knee Osteoarthritis
Interventions: Suzetrigine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Drug Abuse, Intoxication by Drug, Impairment
Interventions: Placebo, THC, CBD, THC + CBD; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium, Computed Tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy, Magnetic Resonance Imaging, Photoimmunotherapy, Positron Emission Tomography, Robotic Bronchoscopy, Video-Assisted Thoracic Surgery; Procedure · Biological · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Feasibility Trial of the Womb Watch Smartphone App To Assess Fetal Movements

Vagus Nerve Stimulation to Enhance Memory in Aging

IA Lidocaine and Methylprednisolone for Headache Associated With Subarachnoid Hemorrhage

Planning Actions for Consistent Engagement

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

Feasibility of Addressing Sexual Dysfunction in Women with Breast and Gynecologic Cancers with a Novel Mobile Application

Postural Motor Activation Deficits After mTBI; Translating Laboratory Findings to Clinical Care

Consciousness Studies and Cardiovascular Health

Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

Feasibility and Acceptability of Three Component Intervention for the Heart Failure Care for Rural Dwelling Participants

Topical Curcumin for HPV Related Cervical Disease

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

The ORCHESTRATE-Myocarditis Registry

Mochida ReFeel for Digital Nerve Injuries

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Implementation Guided by aN Iterative, adapTivE Strategy - Induction of Labor

NeuroCuple to Mitigate Post-Wisdom Teeth Extraction Opioid Risks

Brighter Bites/Legacy Produce Rx Program

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

Evaluation of Oral THC and CBD in Men and Women

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer